Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Terminated Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01192815Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and NeckTreatment